Joel Beevers
Passionate about biopharma and health-related inventions, Joel helps clients maximise exclusivity for their IP, whether this involves pushing boundaries or adopting pragmatic solutions. With a keen eye for detail, he understands both the nuances and the bigger picture of a client’s portfolio.
Joel helps protect new and existing products with the potential to improve human and animal health. He is a trusted advisor on the drafting and prosecution of patent applications and the management of an intellectual property (IP) portfolio. He also specialises in supplementary protection certificates (SPCs) for high-value medicinal products and closely follows legal developments from the Court of Justice of the European Union (CJEU).
With a strong background in research, particularly around neurodegenerative disease, Joel identifies and nurtures new IP opportunities from pre-clinical and clinical data. His attention to detail also delivers results when attacking or defending patents during oppositions at the European Patent Office (EPO).
Joel contributes to the IP community as a member of the Life Sciences Committee of the Chartered Institute of Patent Attorneys (CIPA) in the UK.
- Helping pharmaceutical companies assess the value of potential acquisitions through due diligence of patents and SPCs
- Advising on patenting new uses for existing products
- Successfully revoking European life sciences patents during opposition proceedings
- UK and European Patent Attorney
- DPhil, Physiology, Anatomy and Genetics, University of Oxford
- MSc, Neuroscience, University of Oxford
- BSc, Biochemistry with Industrial Placement, University of Leeds
- Moss Prize (2018): Highest combined mark in UK Patent Law and International Patent Law foundation exams
About Joel
Experience
Areas of expertise
Qualifications
Testimonials
Awards
How We Live Our Values: Excellence
A hallmark of my career is making legal concepts and information clear and genuinely useful to others. I’ve written many legal updates for the firm’s website, especially on SPC law, explaining complex issues in a way that brings out the key concepts and take-home actions that matter. That same approach carries through to my work with clients and overseas attorneys. For advice to be valuable and meet the level of quality clients expect from us, action points need to be clearly identified and explained in a straightforward way.
In My Own Words
Near the end of my PhD, I knew I wanted to find a fulfilling science career outside of the lab, somewhere I could use my skills and interest in life sciences commercially. I soon came across the patent profession and realised I could have the best of both worlds, using my scientific understanding while building relationships with clients and colleagues.
I love that I now get to work with a wide variety of technologies and clients around the world. I support the commercialisation of everything from probiotics to high-value drugs, from vaccines to medical devices. New areas of technology are constantly developing, and being a patent attorney keeps me at the cutting edge, only now I’m on the other side of the poster presentations.
Related News
.jpg)
UK SPC law changes from 1 January 2025: what you need to know
No post-Brexit return to second medical use SPCs: Court of Appeal upholds refusal of Merck Serono SPC in the UK
High Court upholds UKIPO decision: Halozyme's SPC appeal dismissed
CJEU swiftly deals with Genmab SPC application in reasoned order
Excipient or active ingredient? CJEU requested to rule on Articles 1(b) and 3(a) of the SPC Regulation
Reconfiguring the two-part test: Advocate General proposes SPC solution in favour of generics
Legal Limbo: Genmab’s ofatumumab SPC dilemma heads to CJEU
